Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2017

View Archived Issues

Heat Biologics set to acquire Pelican Therapeutics

Diamyd Medical invests in NextCell Pharma

Eurostars grant awarded to international consortium developing antibody-drug conjugates

YY-1 protein as a potential prognostic marker in Wilms' tumor

ImmunoMet Therapeutics raises series B financing

Inhibikase receives research grant from The Michael J. Fox Foundation

IDO-1, a potential biomarker for cancer of the biliary tract

Pharnext and Galapagos collaborate to generate pipeline of synergistic drug combinations

First-in-human study of AAGP-treated islet cells for type 1 diabetes

Beijing Hanmi Pharmaceutical patents IRAK-4 inhibitors

Karyopharm Therapeutics presents serine/threonine-protein kinase modulators

FORUM Pharmaceuticals discovers oxadiazine compounds

PKU HealthCare Industry Group presents phosphatidylinositol 3-kinase alpha inhibitors

Janssen Pharmaceutica identifies protein arginine N-methyltransferase 5 inhibitors

Bavarian Nordic and Roche collaborate to study Tecentriq with CV-301 for bladder cancer

Synairgen reports new data from LOXL2 enzyme inhibitor program in IPF

Vasodilator-stimulated phosphoprotein as potential diagnostic marker for papillary thyroid carcinoma

CD163-positive M2-like macrophages correlate with patient survival in esophageal adenocarcinoma

FDA clears IND for UCART-19

Zinplava approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
XPC-837 restores network dysfunction in Dravet syndrome models
BioWorld Science
Researchers from Xenon Pharmaceuticals Inc. described the preclinical efficacy of XPC-837 in models of Dravet syndrome, a severe developmental and epileptic...